Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SonoSight (SONO), Handheld ultrasound for the masses -- Ignore unavailable to you. Want to Upgrade?

To: caveat who wrote (340)	2/2/2000 9:02:00 PM
From: Sam	Read Replies (1) \| Respond to of 365

It hasn't updated since their last secondary a couple of months ago. The "float" isn't actual shares outstanding, it's how many can trade without filing with the SEC first (unrestricted as opposed to restricted shares). I picked up some shares today. Unfortunately I paid $29. So it goes.

To: caveat who wrote (340)	2/2/2000 9:41:00 PM
From: Jack Hartmann	Read Replies (1) \| Respond to of 365

Some Prudential analyst notes on SONO from the 2/2/00 report. Marketcap - 299M Shares Out - 9.2M est Float - 7.4M est Given a "strong buy" 12 mo. price target of $38 (ultra conservative) based 7 times CY00 revenue. 4Q rev was 2.2M higher than estimated. Increased sales and marketing accounted for the higher EPS loss. Hired 27 clinical sonographers to focus on hospital sales. 49.5M est rev for the year. "Internationally, distributor sales are strong, contributing 60% of revenues in the fourth quarter" 01/00Quarter should have a drop in revenue as orders from distibutors are worked off. When the MM gapped SONO down to $26, there were no big buy orders so they probably used it as an opportunity to accumulate some cheap shares on weak holders selling in a panic. I feel the $38 target also allows Prudential (who makes a market in SONO) to get cheap shares also as some holders buy and sell off these targets. Prudential has been very conservative in its targets in biotech (Like CYTC). Don't let this action today bother anyone. ASPM has a 585M market cap and is similar to SONO in that they have a single medical device that is used by hospital. I expect SONO to be $50 by the end of December and that is conservative using similar revenue and market capitalization. Revenue growth is great for the company with only portable FDA approved ultrasound device. $2.5M in R&D is not going to maintain one product, but to develop more uses for routine imaging of patients. Jack